D. E. Wilson, E. Quadros, T. Rajapaksa
Feb 1, 1986
Citations
0
Influential Citations
28
Citations
Quality indicators
Journal
Digestive Diseases and Sciences
Abstract
Misoprostol, a synthetic prostaglandin E1 analog, at doses of 200, 400, or 800 μg, and placebo were administered orally in random fashion to eight healthy male volunteers. The effects on basal and pentagastrin (0.6 μg/kg/hr)-stimulated acid and mucus (N-acetylneuraminic acid measurement) secretion were then determined. Misoprostol in 200-, 400-, and 800-μg doses reduced basal acid secretion by 91%, 93%, and 93%, respectively. Mean 2-hr acid secretion was reduced by 27%, 33% (P<0.01), and 51% (P<0.01), respectively. Reductions in secretory volumes paralleled acid changes. Mucus secretion increased by 37%, 82%, and 95% during the basal period following misoprostol doses of 200, 400, and 800 μg, respectively. Increase in mucus of 27%, 31%, and 38% was observed during maximal acid inhibition (1–30 min) by misoprostol in 200-, 400-, and 800-μg doses. The concentration of gastric juice mucus was significantly increased. Subjects experienced no significant side effects during the study, and there were no significant changes in hematological or chemical blood studies. Misoprostol, a potent inhibitor of gastric acid secretion, also stimulates mucus secretion. This mucogenic effect may be important in the mucosal protective action of misoprostol and its antiulcer efficacy in man.